Wegovy pill causes 15% increase in UK obesity drug prescriptions by 2026
Resolves: UK total prescriptions for obesity drugs (including Wegovy pill and other GLP-1 agonists) in Q4 2026 show a 15% increase compared to Q4 2025, per NHS prescription data or equivalent authoritative source.
Wegovy pill causes 15% increase in UK obesity drug prescriptions by 2…
Market overview
The introduction of the oral Wegovy pill will accelerate the adoption of GLP-1 receptor agonist drugs in the UK, leading to a 15% year-over-year increase in total obesity-related prescriptions by the end of 2026. This growth will be fueled by patient preference for oral medications and expanded access via private pharmacies.
adoption prediction market
- Implied probability (Yes)
- 68%
- Closes
- 2026-12-31
About this prediction
Resolution criteria
UK total prescriptions for obesity drugs (including Wegovy pill and other GLP-1 agonists) in Q4 2026 show a 15% increase compared to Q4 2025, per NHS prescription data or equivalent authoritative source.
Source: user-generated
More adoption markets
- Daily active crypto users surpass 100 million by mid-2026 — 60% Yes
- Kalshi’s market share in crypto derivatives surpasses 5% by Q4 2027 — 55% Yes
- Kalshi's crypto perpetual futures launch by 2026-Q4 — 75% Yes
- Family offices double down on crypto-adjacent mining firms within 6 months — 72% Yes
- Nigeria's crypto transaction volume exceeds $5B in 2026 — 80% Yes
- AI and crypto groups increase political ad spending in 2026 midterms — 80% Yes
- Crypto and AI groups double political ad spending by 2027 — 75% Yes
- Crypto billionaire Harborne will increase donations to Farage by 20% by Mar 2027 — 60% Yes